Journal of Chemical and Pharmaceutical Research (ISSN : 0975-7384)

header
Reach Us reach to JOCPR whatsapp-JOCPR +44 1625708989
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Original Articles: 2014 Vol: 6 Issue: 6

study of two brands of cefuroxime 500 mg tablets (Bioxime?® and Zinnat?®) in adults healthy volunteers

Abstract

A bioequivalence study of two oral formulations of Cefuroxime Axetil 500 mg Bioxime ® (Pharmacare International Manufacturing Co., Yemen) as the test and Zinnat ® (GlaxoSmithKline, UK) as the reference product was carried out in 26 healthy male & female volunteers (one drop out) following a single dose, two sequence, two period, two-treatment cross-over design. Both test and reference tablets were administered to each subject after an overnight fasting on two treatment days separated by an one-week washout period. After dosing, serial blood samples were collected for a period of 8 h. Serum harvested from blood was analyzed for Cefuroxime by a sensitive, selective, reproducible and accurate high pressure liquid chromatography (HPLC) me t h o d . Various pharmacokinetic parameters AUC0-t, AUC0-∞ , Cmax, Tmax, T1/2 and Kel were determined from Serum concentrations of both formulations and found to be in good agreement with reported values. AUC0-t, AUC0-∞, Cmax were tested for bioequivalence after log-transformation of data. No significant difference was found based on analysis of variance (ANOVA), 90% confidence interval for test/reference ratio of these parameters was found within bioequivalence acceptance range of 80-125%. Based on these statistical inferences, it was concluded that Bioxime® is bioequivalence to Zinnat®. Both products were well tolerated

rtp slot demo